Dacomitinib (PF-00299804) + Gefitinib
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-small Cell Lung Cancer With EGFR-Activating Mutations
Conditions
Non-small Cell Lung Cancer With EGFR-Activating Mutations
Trial Timeline
May 9, 2013 → Jan 27, 2022
NCT ID
NCT01774721About Dacomitinib (PF-00299804) + Gefitinib
Dacomitinib (PF-00299804) + Gefitinib is a phase 3 stage product being developed by Pfizer for Non-small Cell Lung Cancer With EGFR-Activating Mutations. The current trial status is completed. This product is registered under clinical trial identifier NCT01774721. Target conditions include Non-small Cell Lung Cancer With EGFR-Activating Mutations.
What happened to similar drugs?
20 of 20 similar drugs in Non-small Cell Lung Cancer With EGFR-Activating Mutations were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01774721 | Phase 3 | Completed |
Competing Products
20 competing products in Non-small Cell Lung Cancer With EGFR-Activating Mutations